Banca de DEFESA: VANESSA VIEIRA LACERDA MENEZES

Uma banca de DEFESA de MESTRADO foi cadastrada pelo programa.
STUDENT : VANESSA VIEIRA LACERDA MENEZES
DATE: 28/03/2024
TIME: 14:00
LOCAL: CPF - Sede sala de reuniões - online: meet.google.com/gsh-vhhp-png
TITLE:

SALIVARY INFLAMMATORY MEDIATORS PROFILE ASSOCIATED WITH PHOTOBIOMODULATION APPLIED TO THE TREATMENT OF ORONASAL DISORDERS FROM COVID-19

KEY WORDS:

Taste and smell disturbances; Photobiomodulation, COVID-19.

PAGES: 70
BIG AREA: Ciências da Saúde
AREA: Medicina
SUMMARY:

Taste and smell disturbances (TSD) as sequelae of COVID-19 are a relevant health problem that affect patients' quality of life, without any effective treatments or protocols to mitigate these conditions. The pathophysiology of APO is not yet known, but it is speculated that the maintenance of chronic inflammation might contribute to the persistence of these symptoms. In this study, we sought to evaluate photobiomodulation (PBM) as a therapeutic possibility for controlling changes in taste and smell resulting from COVID-19. We also evaluated whether PBM interferes with the profile of salivary inflammatory mediators. Then, 23 individuals with APO were allocated into 3 groups, according to the therapeutic protocol (oral-PBM, n=11; nasal-PBM, n=8; and sham, n=5); additionally, ten individuals without complaints of disturbances in smell and taste, were enrolled as a control group. Patients in the oral-PBM and nasal-PBM groups were treated with photobiomodulation therapy (PBMT), at a wavelength of 810nm, with different protocols, in 10 clinical sessions, applied at a minimum interval of 48h, while in the sham group, the laser application was simulated. Disturbances in taste and smell (measured using the Connecticut olfactory test, CCCRC and the adapted Mueller taste test) were characterized at the beginning of treatment and after the 5th and 10th PBM sessions, when saliva was also collected for identification of inflammatory mediators. We observed an increased expression of MPO, IL-1β, IL-8 and IL-10 in the saliva of patients with TSD compared to the control group. Furthermore, we found that PBM interfered with the perception of taste and smell in patients with oronasal disorders resulting from COVID-19, but did not significantly change the concentration of NO, MPO, IL-1β, IL-6, IL-8, IL-10 and TNF-α in saliva after 10 PBM sessions, regardless of the protocol adopted. These results indicate that PBM is a promising therapy for controlling TSD, however, the mechanisms that lead to clinical improvement in patients are not associated with changes in the profile of inflammatory mediators in saliva.

COMMITTEE MEMBERS:
Interno - 3067563 - EZEQUIEL BATISTA DO NASCIMENTO
Presidente - 1002463 - HAYANA RAMOS LIMA
Externa à Instituição - IUKARY OLIVEIRA TAKENAMI - UNIVASF
Externa à Instituição - MANOELA CARRERA - UFBA